SKYRIZI®
Risankizumab (ABBV-066) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis, psoriatic arthritis and Hidradenitis Suppurativa.
Type of Molecule
BiologicTarget
IL-23Product Type
New Indication| Potential Indication | Region | Phase (1, 2, 3, Submitted) |
|---|---|---|
| Crohn's Disease | n/a |
Phase 3
|
| Psoriatic Arthritis | n/a |
Submitted
|
| Psoriasis | US,EU |
Approved
|
| Ulcerative Colitis | n/a |
Phase 3
|
| Hidradenitis Suppurativa | n/a |
Phase 2
|